The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

The ubiquitin-like SUMO proteins covalently modify protein substrates and regulate their functional properties. In a broad spectrum of cancers, the tumor suppressor PML undergoes ubiquitin-mediated degradation primed by CK2 phosphorylation. Here, we report that the SUMO E3-ligase inhibitor PIAS1 regulates oncogenic signaling through its ability to sumoylate PML and the PML-RARA oncoprotein of acute promyelocytic leukemia (APL). PIAS1-mediated SUMOylation of PML promoted CK2 interaction and ubiquitin/proteasome-mediated degradation of PML, attenuating its tumor suppressor functions. In addition, PIAS1-mediated SUMOylation of PML-RARA was essential for induction of its degradation by arsenic trioxide, an effective APL treatment. Moreover, PIAS1 suppression abrogated the ability of arsenic trioxide to trigger apoptosis in APL cells. Lastly, PIAS1 was also essential for PML degradation in non-small cell lung carcinoma (NSCLC) cells, and PML and PIAS1 were inversely correlated in NSCLC cell lines and primary specimens. Together, our findings reveal novel roles for PIAS1 and the SUMOylation machinery in regulating oncogenic networks and the response to leukemia therapy.

[1]  Paul Freemont,et al.  Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor α Degradation , 2001, The Journal of experimental medicine.

[2]  E. Yeh,et al.  Identification of Three Major Sentrinization Sites in PML* , 1998, The Journal of Biological Chemistry.

[3]  P. Pandolfi,et al.  Loss of the tumor suppressor PML in human cancers of multiple histologic origins. , 2004, Journal of the National Cancer Institute.

[4]  M. Lanotte,et al.  Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes , 2001, Oncogene.

[5]  P. Pandolfi,et al.  In vivo analysis of the role of aberrant histone deacetylase recruitment and RARα blockade in the pathogenesis of acute promyelocytic leukemia , 2006, The Journal of Experimental Medicine.

[6]  K. Shuai,et al.  Regulation of gene-activation pathways by PIAS proteins in the immune system , 2005, Nature Reviews Immunology.

[7]  H. Yasuda,et al.  Involvement of PIAS1 in the sumoylation of tumor suppressor p53. , 2001, Molecular cell.

[8]  Zhu Chen,et al.  Acute promyelocytic leukaemia: novel insights into the mechanisms of cure , 2010, Nature Reviews Cancer.

[9]  B. Raught,et al.  PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. , 2010, Cancer cell.

[10]  Jian-Hua Tong,et al.  Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.

[11]  Shwu‐Yuan Wu,et al.  Crosstalk between sumoylation and acetylation regulates p53‐dependent chromatin transcription and DNA binding , 2009, The EMBO journal.

[12]  K. Shuai,et al.  The Ligase PIAS1 Restricts Natural Regulatory T Cell Differentiation by Epigenetic Repression , 2010, Science.

[13]  Pier Paolo Pandolfi,et al.  The mechanisms of PML-nuclear body formation. , 2006, Molecular cell.

[14]  Xin-Yun Huang,et al.  SUMOylation-regulated Protein Phosphorylation, Evidence from Quantitative Phosphoproteomics Analyses* , 2011, The Journal of Biological Chemistry.

[15]  S. Kogan,et al.  A sumoylation site in PML/RARA is essential for leukemic transformation. , 2005, Cancer cell.

[16]  Per Stehmeier,et al.  Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. , 2009, Molecular cell.

[17]  S. Jackson,et al.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.

[18]  Rosa Bernardi,et al.  Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies , 2007, Nature Reviews Molecular Cell Biology.

[19]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[20]  Mathieu Courcelles,et al.  A Novel Proteomics Approach to Identify SUMOylated Proteins and Their Modification Sites in Human Cells* , 2010, Molecular & Cellular Proteomics.

[21]  P. Freemont,et al.  PML protein isoforms and the RBCC/TRIM motif , 2001, Oncogene.

[22]  Yang Xie,et al.  Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology , 2008, Nucleic acids research.

[23]  Pier Paolo Pandolfi,et al.  PML regulates p53 acetylation and premature senescence induced by oncogenic Ras , 2000, Nature.

[24]  S. Müller,et al.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[26]  M. Lei,et al.  Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway , 2008, Nature Cell Biology.

[27]  M. Tatham,et al.  RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation , 2008, Nature Cell Biology.

[28]  J. Sobczak-Thépot,et al.  The PML growth-suppressor has an altered expression in human oncogenesis. , 1995, Oncogene.

[29]  P. Pandolfi,et al.  A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor , 2006, Cell.

[30]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[31]  F. Melchior,et al.  Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.

[32]  P. Pandolfi,et al.  The theory of APL revisited. , 2007, Current topics in microbiology and immunology.